Rifabutin Is Active against Mycobacterium abscessus in Mice

Authors:
Open Access
Publisher website
Google Scholar
Abstract
There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus . Here, we report that rifabutin is as active as clarithromycin against M. abscessus K21 in NOD.CB17-Prkdc scid /NCrCrl mice. This suggests that rifabutin should be considered a repurposing candidate for patients with M. abscessus disease.
Funding Information
  • HHS | National Institutes of Health (R01AI132374, U19AI142731)
  • HHS | National Institutes of Health (R21AI145396)

This publication has 19 references indexed in Scilit: